Find Funding Opportunities

This Funding Opportunity Announcement (FOA) invites applications for basic and translational research on the impact of the microbiome on Alzheimers Disease and Alzheimers Disease Related Dementias (AD/ADRD). While there is growing evidence that the microbiome is an important factor that contributes to overall health and a variety of diseases and disorders, the role of the alimentary canal and other sources of endogenous microbiota in specific AD/ADRDs has not been adequately addressed. This FOA will support mechanistic research focused on a more rigorous in-depth examination of the potential interactions between the microbiome and genetic and non-genetic molecular targets that influence AD/ADRD. It is expected that these studies will address the clinical relevance of the microbiome on disease initiation, progression, or modification, and will lead ultimately to better therapeutic interventions.

The purpose of this initiative is to solicit applications for Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. These Centers promote collaborative basic, translational, and clinical research, and provide important resources that can be used by the national muscular dystrophy research community. The Centers also provide outstanding environments for the training of new scientists electing to pursue careers conducting research in high priority areas of muscular dystrophy. Furthermore, Center investigators participate in community outreach efforts to increase awareness and convey the importance and implications of their research activities to the patient and advocacy communities.

The purpose of the FOA is to support the structural characterization of protein species associated with Alzheimer's Disease Related Dementias (ADRDs) through the utilization of cryo-electron microscopy (cryo-EM) and cryo-electron tomography (cryo-ET) of proteins expressed in human tissue and cell sources. Studies in response to this RFA should also include the development of research tools and resources to further characterize/validate the protein species. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2019 update to the National Plan to Address Alzheimer's Disease.

This NINDS Notice of Special Interest (NOSI) is announced as part of the current Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional). It invites applications for administrative supplements to address staffing shortages that are significantly impacting the recruitment of participants for NINDS administered AD/ADRD clinical research studies.

The purpose of this funding opportunity announcement (FOA) is to solicit applications for pragmatic clinical trials to decrease or prevent negative clinical outcomes due to vascular contributions to cognitive impairment and dementia (VCID), including locally representative NIH defined populations that experience health disparities in dementia. Examples of responsive projects and interventions that affect VCID outcomes include, but are not limited to, blood pressure control implementation; lifestyle modification using aerobic exercise; and early detection and treatment of VCID risk factors.

FAQs for the RFA

This Funding Opportunity Announcement (FOA) solicits R01 grant applications that propose independent research projects that are within the scientific mission areas of the ?participating NIH Institutes or Centers. This program is intended to support New Investigators and At-Risk Investigators from diverse backgrounds, including those from groups underrepresented in the health-related sciences.Investigators from diverse backgrounds, including those from underrepresented groups (e.g., see NOT-OD-20-031, Notice of NIHs Interest in Diversity), are eligible to apply. Investigators from categories A and B are particularly encouraged to work with their institutions to apply

The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome (DS). This Notice of Special Interest (NOSI) announces NIH support for administrative supplement applications for actively funded projects to meet NIH Down syndrome research objectives related to the NIH INCLUDE Project as listed below.

This Funding Opportunity Announcement (FOA) solicits applications for a Data Management and Coordinating Center (DMCC) to provide infrastructure, data management, and clinical research support for a new network of clinical sites that provide diagnostic services for undiagnosed diseases. The new Network is intended to sustain some of the key research activities currently performed by the Undiagnosed Diseases Network (UDN), an NIH Common Fund program that was established in 2013 and will sunset in 2023. The DMCC will coordinate clinical sites that apply to join the new Network beginning in FY2023 as Diagnostic Centers of Excellence (DCoEs) through a related Resource Access Program (X01) mechanism. The DMCC will support the DCoEs and the NIH intramural Undiagnosed Diseases Program (UDP) by coordinating trans-network research activities, with services managed across three Cores: 1) Administrative Core; 2) Data Management Core, and 3) Clinical Research Support Core.

This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small businesses to submit Small Business Innovation Research (SBIR) grant applications. United States small businesses that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement does not accept clinical trials.